APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Introduction: This study assessed apolipoprotein E (APOE) ε4 carrier status effects on Alzheimer's disease imaging and cerebrospinal fluid (CSF) biomarkers in cognitively normal older adults with significant memory concerns (SMC). Methods: Cognitively normal, SMC, and early mild cognitive impairment participants from Alzheimer's Disease Neuroimaging Initiative were divided by APOE ε4 carrier status. Diagnostic and APOE effects were evaluated with emphasis on SMC. Additional analyses in SMC evaluated the effect of the interaction between APOE and [18 F]Florbetapir amyloid positivity on CSF biomarkers. Results: SMC ε4+ showed greater amyloid deposition than SMC ε4−, but no hypometabolism or medial temporal lobe (MTL) atrophy. SMC ε4+ showed lower amyloid beta 1–42 and higher tau/p‐tau than ε4−, which was most abnormal in APOE ε4+ and cerebral amyloid positive SMC. Discussion: SMC APOE ε4+ show abnormal changes in amyloid and tau biomarkers, but no hypometabolism or MTL neurodegeneration, reflecting the at‐risk nature of the SMC group and the importance of APOE in mediating this risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortical Surface-Based Analysis
Dale, A. M., Fischl, B., & Sereno, M. I. (1999) · NeuroImage · doi:10.1006/nimg.1998.0395 · Cited by 10,910
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Many AD researchers believe that effective treatments for AD will require intervention early in the disease course, even before clinical symptoms [2].”
BackgroundSelf-citationCortical Surface-Based Analysis
Fischl, B., Sereno, M. I., & Dale, A. M. (1999) · NeuroImage · doi:10.1006/nimg.1998.0396 · Cited by 6,147 · cited 1×
“1, as described in previous reports [31,41,42], to extract hippocampal volumes, entorhinal cortex thickness measures, and total intracranial volume (ICV).”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationThe Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“model and previous work in autosomal dominant AD [32] and may suggest a more complicated interaction between CSF and imaging biomarkers of neurodegeneration in the earliest stages of disease.”
Self-citationJessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 15×
“Systematic review: To investigate our primary research question on APOE effects in significant memory concern (SMC), we searched PubMed for: “cognitive complaints (CC),” “subjective cognitive decline (SCD),” “neuroimaging,” and “apolipoprotein E (APOE).””
BackgroundInfluentialSelf-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“In addition, SCD/SMC participants who are carriers of the most commonly reported genetic variant associated with late onset AD, the apolipoprotein E (APOE) ε4 allele, show greater medial temporal lobe (MTL) hypometabolism and atrophy, increased cerebral amyloid, and altered CSF measures of amyloid and tau [22,23,28,29…”
BackgroundMaruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Self-citationVisser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Outcome over seven years of healthy adults with and without subjective cognitive impairment
Reisberg, B., Shulman, M. B., Torossian, C., Leng, L., & Zhu, W. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.10.002 · Cited by 568 · cited 1×
“Previous studies have shown that older adults with SCD/SMC have an increased risk for future progression to AD [5–16] andAD-like changes in neuroimaging and cerebrospinal fluid (CSF) biomarkers [4,13,17–27].”
ResultAD dementia risk in late MCI, in early MCI, and in subjective memory impairment.
Jessen, F., Wolfsgruber, S., Wiese, B., Bickel, H., Mösch, E., Kaduszkiewicz, H., Pentzek, M., Riedel‐Heller, S. G., Luck, T., Fuchs, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.017 · Cited by 511 · cited 1×
“Previous studies have shown that older adults with SCD/SMC have an increased risk for future progression to AD [5–16] andAD-like changes in neuroimaging and cerebrospinal fluid (CSF) biomarkers [4,13,17–27].”
ResultSaykin, A. J., Shen, L., Foroud, T. M., Potkin, S. G., Swaminathan, S., Kim, S., Risacher, S. L., Nho, K., Huentelman, M. J., Craig, D. W., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.013 · Cited by 442
Self-citationGlucose metabolism, gray matter structure, and memory decline in subjective memory impairment
Scheef, L., Spottke, A., Daerr, M., Joe, A., Striepens, N., Kölsch, H., Popp, J., Daamen, M., Gorris, D., Heneka, M. T., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1a8d · Cited by 277
Mosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
Self-citationEvidence of Neuronal Compensation During Episodic Memory in Subjective Memory Impairment
Erk, S. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.80 · Cited by 147 · cited 1×
“Previous studies have shown that older adults with SCD/SMC have an increased risk for future progression to AD [5–16] andAD-like changes in neuroimaging and cerebrospinal fluid (CSF) biomarkers [4,13,17–27].”
ResultSubjective cognitive decline: self and informant comparisons
Caselli, R. J., Chen, K., Locke, D. E. C., Lee, W., Roontiva, A., Bandy, D., Fleisher, A. S., & Reiman, E. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.003 · Cited by 145 · cited 2×
“In fact, informant-based complaints have been shown to provide additional predictive ability for the progression to dementia to self-based complaints [5].”
BackgroundResultSelective changes in white matter integrity in MCI and older adults with cognitive complaints
Wang, Y., West, J. D., Flashman, L. A., Wishart, H. A., Santulli, R. B., Rabin, L. A., Pare, N., Arfanakis, K., & Saykin, A. J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.002 · Cited by 110
Self-citation
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The characterisation of subjective cognitive decline
Jessen, F., Amariglio, R. E., Buckley, R. F., van der Flier, W. M., Han, Y., Molinuevo, J. L., Rabin, L., Rentz, D. M., Rodriguez-Gomez, O., Saykin, A. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30368-0 · Cited by 1,389
Self-citationImplementation of subjective cognitive decline criteria in research studies
Molinuevo, J. L., Rabin, L. A., Amariglio, R., Buckley, R., Dubois, B., Ellis, K. A., Ewers, M., Hampel, H., Klöppel, S., Rami, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.012 · Cited by 575
“Another recent study also found that SCD without cognitive deficit but carriers of the APOE ε4 allele showed abnormal changes in amyloid and tau biomarkers, but no hypometabolism or medial temporal lobe neurodegeneration, reflecting the at-risk nature of the SCD group [52].”
BackgroundSelf-citationSubjective Cognitive Decline in Preclinical Alzheimer's Disease
Rabin, L. A., Smart, C. M., & Amariglio, R. E. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045136 · Cited by 590
Spatial navigation deficits — overlooked cognitive marker for preclinical Alzheimer disease?
Coughlan, G., Laczó, J., Hort, J., Minihane, A.-M., & Hornberger, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0031-x · Cited by 500
Metadata
- Authors
- Risacher, S. L., Kim, S., Nho, K., Foroud, T., Shen, L., Petersen, R. C., Jack, C. R., Beckett, L. A., Aisen, P. S., Koeppe, R. A., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Saykin, A. J., & (ADNI), A. D. N. I.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-05-07
- Volume
- 11
- Issue
- 12
- Pages
- 1417-1429
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1957263655
- Cited by
- 186
- References
- 22
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.